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Abstract
Introduction: The RTS,S/AS01 pre-erythrocytic malaria vaccine is in phase III clinical trials. It is critical to anticipate where
and how it should be implemented if trials are successful. Such planning may be complicated by changing levels of malaria
transmission.
Methods/results: Computer simulations were used to examine RTS,S/AS01 impact, using a vaccine profile based on phase II
trial results, and assuming that protection decays only slowly. Settings were simulated in which baseline transmission (in the
absence of vaccine) was fixed or varied between 2 and 20 infectious mosquito bites per person per annum (ibpa) over ten
years. Four delivery strategies were studied: routine infant immunization (EPI), EPI plus infant catch-up, EPI plus school-
based campaigns, and EPI plus mass campaigns. Impacts in changing transmission settings were similar to those in fixed
settings. Assuming a persistent effect of vaccination, at 2 ibpa, the vaccine averted approximately 5–7 deaths per 1000
doses of vaccine when delivered via mass campaigns, but the benefit was less at higher transmission levels. EPI, catch-up
and school-based strategies averted 2–3 deaths per 1000 doses in settings with 2 ibpa. In settings where transmission was
decreasing or increasing, EPI, catch-up and school-based strategies averted approximately 3–4 deaths per 1000 doses.
Discussion: Where transmission is changing, it appears to be sufficient to consider simulations of pre-erythrocytic vaccine
impact at a range of initial transmission levels. At 2 ibpa, mass campaigns averted the most deaths and reduced
transmission, but this requires further study. If delivered via EPI, RTS,S/AS01 could avert approximately 6–11 deaths per 1000
vaccinees in all examined settings, similar to estimates for pneumococcal conjugate vaccine in African infants. These results
support RTS,S/AS01 implementation via EPI, for example alongside vector control interventions, providing that the phase III
trials provide support for our assumptions about efficacy.
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Introduction
RTS,S/AS01 (RTS,S) is the most advanced malaria vaccine
under development. Work started in the 1980’s, and the phase III,
or final trial prior to seeking regulatory approval, began in 2009 in
Africa [1]. Interim phase III results suggest efficacy against first or
only clinical episode of over 50% [2]. If all goes as planned, the
trial could be completed around 2015.
At the same time, declines in malaria transmission have been
documented in many areas of Africa [3–6]. While these changes
have not been completely explained, and in some places
transmission remains stable [7] or may even be increasing, the
growing use of long lasting insecticide treated bednets (LLINs) and
improved medicines for treating malaria are probably major
causes of the declines [8–16]. However, malaria continues to kill
close to 800,000 people each year, mostly among children under
five years of age living in Sub Saharan Africa [6] and a malaria
vaccine could be a valuable, additional tool to prevent malaria
mortality and morbidity. It is to be hoped that we will see this toll
further reduced by the time RTS,S is available, but both
insecticide and drug resistance represent major threats [17,18]
and malaria programs remain dependent on financially-challenged
donors [19]. It seems likely that RTS,S will be introduced into a
complex mixture of changing patterns of transmission.
Two major mathematical models of malaria and pre-erythro-
cytic malaria vaccines, such as RTS,S, have been published in the
past ten years [20,21]. Both models run probabilistic micro-
simulations in populations of thousands of people. The models are
systematically fitted to an extensive library of field data from
varying transmission settings. The transmission in an area is
reflected by the entomological inoculation rate (EIR), which is a
direct measure of the number of infectious mosquito bites per
person per annum (ibpa). In the published model studies, the EIR
is modeled at fixed levels of 2, 5, 11, 20, 42, 84, and 168 infectious
bites per annum (ibpa) [22–24] or 3, 43, 46 81, 586, and 675 ibpa
[20].
These studies projected that RTS,S is likely to have an
important and varying public health impact, depending on level
of transmission in an area and delivery strategy [20,22–24].
Impact is quantified in terms of reduced transmission and/or cases
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and deaths averted. Impact on cases and deaths, particularly when
delivered to infants via the Expanded Programme on Immuniza-
tion (EPI), is thought likely to be greater in lower to moderate
transmission settings. This is because, in partially protected
individuals in higher transmission settings, vaccination is predicted
to have an effect of shifting some of the burden of disease to older
ages, rather than completely averting it [22,23].
The decision to use RTS,S will partially depend on the impact
sought. For many vaccine preventable diseases, a significant part
of the impact is achieved by transmission reduction via herd
immunity. For malaria transmission reduction, the initial trans-
mission level and the feasibility of the delivery strategy are critical
considerations. Modeling studies suggest that RTS,S will only have
a substantive impact on transmission in areas where it is already
low (e.g. 3 ibpa) [20], and when delivered through mass
campaigns, reaching a large proportion of the entire population
[20,24]. At low EIRs, such as 2 ibpa and below, transmission
becomes more focal and less stable.
EPI programs have delivered infant vaccines in developing
countries for decades. Among African infants in 2009, 73% were
immunized with three doses of Diphtheria-Tetanus-Pertussis
(DTP3) vaccine scheduled at approximately 6, 10 and 14 weeks
of age [25]. This is the same initial schedule as is being anticipated
for RTS,S. The current clinical trials of RTS,S and regulatory
plans include children aged six weeks through 17 months at first
RTS,S vaccination. EPI and catch-up strategies, targeting this age
range, thus represent the near-term options for implementing
RTS,S. When delivered through EPI, RTS,S is likely to have
greatest efficacy and impact in low to medium transmission
settings [22,23], and to be most cost-effective in areas with EIR
from 2–20 ibpa [26]. This suggests that the value of RTS,S, as a
complementary intervention to save lives and prevent morbidity, is
likely to grow in importance with anticipated decreasing
transmission trends resulting from the scaling up of malaria
interventions across Africa. Impact through EPI is questionable in
very high transmission settings (e.g. 168 ipba), where a large
proportion of disease episodes prevented early in life may simply
be experienced with a delay and are thus not fully prevented.
Vaccine delivery strategies other than EPI, such as school-based
and population-wide mass campaigns, target incrementally wider
age ranges and greater numbers of people. Mass campaigns are
estimated to have relatively little impact on mortality and
morbidity at a transmission above an EIR of 5 ibpa [23].
School-based and mass campaign strategies for delivering RTS,S
may require additional multi-year clinical studies and regulatory
decisions, beyond those currently anticipated. They may also
require large, specialized initiatives for which there is limited
precedent, suggesting feasibility studies would be needed.
The recognition that RTS,S may have varying efficacy and
associated impact in different transmission settings has been
considered in the design of its phase III trial: the trial includes 11
sites spread across Burkina Faso, Gabon, Ghana, Kenya, Malawi,
Mozambique, and Tanzania, intended to reflect the wide range of
transmission levels seen in Africa [1]. While possible to select sites
over a range of transmission levels, it was not possible to select sites
according to changing transmission dynamics.
RTS,S is, however, likely to be implemented in environments
where baseline malaria transmission levels are changing. In some
countries still scaling up interventions, transmission will likely be
decreasing. Other countries, after initial successes, may be
struggling to maintain suppressed malaria transmission levels
and may see malaria transmission increase. Predictions of the
potential impact of RTS,S, to be used by policy-makers at global
and country levels [27,28], will need to consider such contexts of
changing transmission. It is unclear if the findings of models using
fixed annual transmission levels hold where annual transmission is
changing.
This paper uses simulations to examine how, depending on the
delivery strategy, the expected impact of RTS,S may be affected
when implemented in the context of increasing or decreasing
malaria transmission trends.
Methods
Simulation model
The models are designed in a modular way to reflect the pathway
from infection to development of disease and death as well as
transmission via the vector and hence herd immunity effects. The
base model [29], comprised modules for acquisition of P. falciparum
infections [30], for regulation of parasite densities [31], for
morbidity [32], for mortality [33] and for case management [34].
The drivers of uncertainty in this model were recently analyzed
using a probabilistic sensitivity analysis [26]. The model ensemble
used in the present study made use of 13 additional models with
different assumptions about decay of immunity, heterogeneities in
exposure, case management, susceptibility and comorbidity.
Comprehensive information on the models is detailed in our recent
study of RTS,S in settings with vectorial capacities oscillating
seasonally around fixed values, including their main assumptions
and the model fitting (Text S1) [24].
The 14 models were parameterized using 61 datasets and fit
against 10 epidemiological outcome measures described previously
[21,24]. The contribution of each outcome was calibrated using a
goodness of fit statistic reflected by the weighted sum of each log-
likelihood contribution. The fit was confirmed if the models
adequately reproduced the age-specific patterns of infection and
morbidity from the original data sets.
Each model run was a stochastic simulation of a stable
population of 100,000 people, run with five day time steps for
an observation period of 10 years. The simulated populations had
approximately stationary age-distribution typical of rural Tanza-
nia, achieved by adjusting birth and out-migration rates to the
required values [31].
The models were programmed in C++ as part of the open
source software platform OpenMalaria (http://code.google.com/
p/openmalaria/). SAS GPLOT was used to generate the figures
(SAS Institute Inc., Cary, NC, USA, version 9.2 for Windows).
Transmission settings
In the absence of vaccination, baseline transmission was
modeled to follow the seasonal patterns observed in Namawala,
Tanzania, as in previous studies [22,24], but with the EIR scaled
to be in the range of 2 ibpa to 20 ibpa. Although transmission
becomes less stable at the lower end of this range, a consistent
cycle of transmission was assumed for the purposes of the
modeling, unless changed as described below. In this range,
comparable to EIRs achievable with existing interventions in most
of rural Africa, the previous modeling studies suggest that RTS,S
will be highly effective. In each case, the initial immune status of
the simulated humans was set to that of a population recurrently
exposed to an EIR of 20 ibpa. Simulations of vector control
programs were then implemented so that in the absence of
vaccination, the profile of transmission during the period of the
vaccination program followed one of the following seven patterns
(Figure 1):
a) EIR= 11 ibpa, approximately, throughout the ten year
observation period.
RTS,S Impact in Changing Malaria Transmission
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b) EIR = 2 ibpa, approximately, throughout the ten year
observation period.
c) Decreasing: EIR decreasing linearly from 20 down to 2 ibpa
over a ten year period.
d) Increasing after brief suppression: EIR initially reduced to
2 ibpa, then increasing linearly to 20 ibpa over the ten year
observation period.
e) Increasing after ten years suppression: EIR which had been
brought from 20 down to 2 ibpa and maintained there for ten
years, increasing again up to 20 ibpa over the ten year
observation period due to decreased use of IRS.
f) Suppressed: EIR decreased rapidly from 20 down to 2 ibpa,
and subsequently maintained at 2 ibpa during the ten year
observation period.
g) EIR = 20 ibpa, approximately, throughout the ten year
observation period.
Settings a, b, and g correspond to settings with stable
transmission. In these cases, the populations were simulated as
having been exposed to these EIRs for a warm-up period
corresponding to a full lifetime, before the start of the observation
period during which vaccines were introduced.
Settings c, d, e, and f had changing baseline levels of
transmission. The simulated populations were exposed to an
annual EIR of 20 ibpa during the ‘warm-up’ period but then
changes in the transmission, and hence the EIR during the
observation period were induced by simulating IRS programs
carried out in parallel with the simulated vaccination programs.
The simulated coverage and effectiveness of the IRS programs
were adjusted to achieve approximately linear trends in EIR in the
absence of vaccination [35,36].
Vaccine efficacy and half life
RTS,S was modeled to have an efficacy of 60% against the force
of infection from the time of completing the full, three dose
vaccination course. The same moderate level of heterogeneity
among individuals in the level of protection was assumed as in
previous simulations [24,37]. Efficacy after a single dose and two
doses was modeled as 40% and 50%, respectively. The intention-to-
treat analysis included in the most recent RTS,S trial publication,
suggests that a substantial proportion of the efficacy may be reached
before completion of the vaccination schedule [2]. A field study
including a two-dose schedule using immunologic endpoints found
that all subjects had significant responses, however, as there are no
protective thresholds established, there is no way to determine the
associated efficacy [38]. Immunologically it is reasonable to assume
that three doses will strengthen the immune response and lengthen
the duration of protection as compared to fewer doses. Previous
analyses of our models showed that results are not very sensitive to
the (extreme) assumption that the vaccine has no efficacy in those
who do not receive all three doses. In the case of EPI, the results
change very little given that coverage with all three doses tends to be
very high. In case of school-based and mass campaigns, the study
found that effectiveness against mortality relative to previous levels
was 0.91 (95% CI 0.61–1.65) or 0.58 (95% CI 0.04–1.00)
respectively [24]. Efficacy against clinical disease in these models
is lower than efficacy against force of infection [24,37], as is the
efficacy against severe disease found in a clinical trial. Field studies
have not yet associated efficacy against clinical disease with efficacy
against deaths.
Vaccine efficacy against force of infection was modeled to decay
exponentially with a half-life of ten years. The relatively short
and/or small field studies undertaken to date have not provided
clear trial data on decay of efficacy of RTS,S. Past modeling has
suggested that vaccine impact is not particularly sensitive to the
length of the half-life in the 4–10 year range [22], and has been
used to derive calibration curves that can be used to convert the
predictions for long half-life vaccines to approximate values for
shorter half-lives (Text S1) [24]. Clinical efficacy observed in trials
is expected to wane more rapidly than the underlying efficacy
against the force of infection [24] because the age-pattern of
disease in vaccinees begins to mimic that of an area with lower
transmission in which disease is delayed to an older age [39,40].
Figure 1. Simulated transmission settings. Legend: a (dashed purple line): EIR = 11 ibpa; b (dashed black line): EIR = 2 ibpa; c (solid black line):
EIR decreasing from 20 down to 2 ibpa over 10 years; d (solid green line): EIR increasing after brief suppression from 2 to 20 ibpa over 10 years; e
(solid orange line): EIR increasing from 2 to 20 ibpa after being suppressed for 10 years; f (solid purple line): EIR suppressed from 20 down to 2 ibpa,
and subsequently maintained at 2 ibpa; g (dashed orange line): EIR = 20 ibpa.
doi:10.1371/journal.pone.0032587.g001
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Vaccine delivery strategy
Four delivery strategies were considered:
(i) EPI. Coverage of 89%, based upon Tanzania’s DTP3
coverage in 2002. 95% of subjects received one dose, 93%
two doses, and 89% all three doses at intervals as described
in the introduction.
(ii) EPI plus catch-up. In addition to delivery through EPI (i
above), as the vaccine is first introduced into an area,
children too old for EPI up to 18 months of age were
vaccinated at monthly campaigns with three doses. No
child received more than three doses. Coverage of children
through campaigns was 80% selecting randomly for each
dose, thus 51% of children up to 18 months of age received
all three doses.
(iii) EPI plus vaccination of school children. In addition to
delivery through EPI (i above), primary school age children
(aged 6 to 11 years) were vaccinated in monthly campaigns
with three doses at program initiation only. Coverage of
children through campaigns was 80% [41] selecting
randomly for each dose, thus 51% of children 6–11 years
of age received all three doses. Each subsequent year, only
new students were vaccinated. Children who were initially
vaccinated as infants received a single (booster) dose upon
entry into the school system, also at 80% coverage.
(iv) Mass vaccination. People from all ages were vaccinated in
an initial campaign for three doses at one month intervals.
Coverage through campaigns was 80% [42] selecting
randomly for each dose, thus 51% of people of all ages
receive all three doses. Subsequent campaigns delivered a
single booster to 80% of the population every five years.
Table 1 summarizes the scenarios, and their justifications, used
in the simulations.
Results
Number of doses required
Figure 2 shows the cumulative number of doses per capita (in
the all age population) required for each delivery strategy over a
ten year period. EPI (strategy i), vaccinating infants from six weeks
of age, required the fewest doses, ranging from 0.67/capita over
five years to 1.50/capita over ten years. For a population of
100,000 this is equivalent to 67,000 doses over five years and
150,000 over ten years. An EPI plus catch-up strategy (ii), which
involves a single campaign in the first year, targeting the cohort of
children up to 18 months of age, required an additional 0.10
doses/capita. The EPI plus school-based strategy (iii), which
assumed 51% of kids fully vaccinated, required 1.14 doses/capita
over five years and 2.12/capita over ten years. The mass campaign
(strategy iv), which assumed 51% of the population fully
vaccinated, progressed in a stepped fashion. The year-one
campaign required 2.37 doses/capita, or 237,000 for a population
of 100,000. A total of 3.38 doses/capita was required after the
booster in year five.
Impact of delivery strategy on transmission
Figure 3 presents the impact of RTS,S, delivered through EPI
or mass vaccination, on malaria transmission over a ten year
period, in each transmission setting. These were similar to those
with EPI alone. The results for the setting of EIR= 20 ibpa is not
shown as it was similar to the setting of EIR=11 ibpa.
The annual patterns were a result of seasonality of vector
abundance and the timing of the IRS rounds, if implemented.
Table 1. Summary of scenarios used in simulations.
Category Assumption Value Source
Transmission Unchanging 11 ibpa Estimate
Unchanging 2 ibpa Estimate
Decreasing 20 to 2 ibpa over 10 years Estimate
Increasing after brief suppression 2 to 20 ibpa over 10 years Estimate
Increasing after 10 year suppression 2 to 20 ibpa over 10 years Estimate
Suppressed 20 to 2 ibpa and maintained Estimate
Unchanging 20 ibpa Estimate
Vaccine coverage
(1, 2 or 3 doses)
EPI 95%; 93%; 89% WHO, http://apps.who.int/immunization_monitoring/en/
globalsummary/countryprofileselect.cfm; Accessed November 30, 2011
Campaign or booster dose 80% at each dose, selecting randomly [41,42]
Efficacy 3 doses 60% [24,37]
2 doses 50% Estimate
1 dose 40% Estimate
Half-life Exponential decay 10 years Estimate, [22,24]
Delivery strategy EPI Up to 3 doses at 6, 10, and 14 weeks
of age
WHO, http://www.who.int/immunization/policy/
Immunization_routine_table2.pdf; Accessed November 30, 2011
EPI plus catch-up campaign EPI plus up to 3 doses for children up
to 18 months
Estimate
EPI plus school campaign EPI plus single booster at school entry
or 3 doses for children 6 to 11 years
[41]
Mass campaign 3 doses to people of all ages with
single booster every 5 years
Estimate
Legend: EPI = Expanded Programme on Immunization; ibpa = infectious bites per annum.
doi:10.1371/journal.pone.0032587.t001
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Consistent with past analyses using a fixed level of transmission
[20,23], RTS,S did generally not have much impact on
transmission in the higher EIR ranges modeled. At EIR= 2 ibpa,
whether naturally occurring, or suppressed to that level through
use of IRS, the vaccine lowered transmission initially when
delivered through mass campaigns but the effect leveled off after
seven years.
Impact on uncomplicated malaria cases
Table 2 presents the number of uncomplicated malaria cases
experienced in each setting and the percentage of those cases
which could be averted by RTS,S, depending on the delivery
strategy.
All-age rates of uncomplicated disease in simulated stable
settings were rather insensitive to the average level of EIR,
corresponding to the data used to fit the models [32,43], where the
effect of varying transmission is to shift the age-pattern, rather than
the overall incidence of uncomplicated disease. However, changes
in EIR, and in particular an increase in transmission has a
substantial effect on simulated incidence. In the absence of
vaccination, each person was estimated to have between 1.35 cases
per year (in a decreasing transmission setting) and 2.97 cases
(setting where control was lost).
EPI averted 3.4–6.0% of malaria cases depending on the
transmission, while EPI plus catch-up averted 4.1–8.6% of cases.
EPI plus school-based strategies averted 8.3–17.6% of cases,
depending on transmission, while mass campaigns averted 15.5–
73.0% of cases. The range of estimates was widest for the mass
campaign strategies and most narrow for EPI strategies, and
overlapped for these two strategies in transmission scenario g
(EIR=20 ibpa).
Figure 4 presents the ratio of uncomplicated cases averted
to1000 doses administered. This standardized measure allows
comparison of the efficiency of different delivery strategies across
transmission settings.
Across all settings, the cumulative number of cases averted
per1000 doses was highest with mass campaigns, followed by EPI
plus school, EPI plus catch-up, and EPI alone. After ten years, EPI
and EPI plus catch-up averted 500–700 cases per 1000 doses
across all settings. An EPI plus school-based strategy averted 800–
1100 cases per 1000 doses across all settings. Results from mass
campaigns were more variable. In settings with EIR=11 ibpa
(Panel A), decreasing EIR (Panel C), and increasing EIR after a
brief suppression (Panel D), RTS,S averted 1100–1300 cases per
1000 doses. In a setting with EIR increasing after ten years
suppression (Panel E), it averted approximately 2000 cases per
1000 doses from year eight onwards but the effect appeared to be
plateauing. In a setting with EIR suppressed to 2 ibpa (Panel F), it
averted a similar ratio of cases over the ten year period, but the
curve suggested increasing efficiency beyond year ten. The highest
efficiency was seen in EIR=2 ibpa where the models predicted
that RTS,S could avert more than 2000 cases per 1000 doses after
5–8 years.
Impact on malaria deaths
Table 3 presents the number of malaria deaths, per 1000
person-years, occurring in each transmission setting, and the
percentage of deaths which simulations suggested could be averted
by RTS,S. Figure 5 complements this data, presenting the
cumulative deaths averted per 1000 persons over 10 years for
each of the 14 models.
Delivery through EPI was estimated to avert 6.8–15.5% of
malaria deaths, depending on the transmission, while EPI plus
catch-up averted 7.2–17.2% of deaths. EPI plus school-based
strategies averted 13.6–22.4% of malaria-related deaths, depend-
ing on transmission, while mass campaigns averted 9.9–68.1% of
these deaths. The upper estimates of the ranges for mass
campaigns likely reflected the effect of herd immunity magnifying
the impact of the vaccine. The ranges of model medians from EPI
and mass campaign strategies overlapped in all settings except b
and f where EIR was at or suppressed to 2 ibpa, while in setting g
(EIR=20 ibpa), the point estimate of deaths averted was higher
for EPI than from mass campaigns. The ranges of estimates were
widest for the mass campaign strategies and narrowest for EPI
Figure 2. Cumulative doses per capita, by delivery strategy, in a dynamic population. Legend: Black = EPI; Yellow=EPI plus catch-up of
children up to 18 months of age; Brown=EPI plus school-based immunization of children 6–11 years of age; Green=Mass campaigns in entire
population. The per capita estimates assume a dynamic population, modeled upon the age distribution in rural Tanzania.
doi:10.1371/journal.pone.0032587.g002
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Figure 3A–F. Modification of transmission trends, by delivery strategy, over ten years. Legend: The first column corresponds to no
vaccine, the second corresponds to vaccine delivered through EPI and the third corresponds to vaccination through mass campaigns to all ages of
RTS,S Impact in Changing Malaria Transmission
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strategies. This is illustrated by the variation between model
medians shown in Figure 5. The only setting where all model
medians showed higher impact from mass campaigns than from
EPI was in settings with EIR=2 ibpa (Panel B). A high level of
uncertainty was associated particularly with settings where the EIR
was increasing after a brief suppression (Panel D), increasing after
a ten year suppression (Panel E), or continuously suppressed to
2 ibpa (Panel F). The ranking of the different models in mortality
benefits differed by vaccination strategy and transmission intensity,
making it challenging to identify which elements of model
structure drove this uncertainty.
The efficiency of RTS,S averting deaths is presented as a ratio
of the number of deaths averted to1000 doses administered
(Figure 6). The results for the setting of EIR= 20 ibpa is not shown
as it was similar to the setting of EIR= 11 ibpa.
Across all settings, the cumulative number of deaths averted per
1000 doses of RTS,S generally leveled off at a maximum of 3–4.
Such efficiency was realized only after approximately seven years in
settings with increasing transmission, either after brief or ten year
suppression (Panels D and E), while it was reached after only two to
three years in the setting with decreasing transmission (Panel C) with
delivery through EPI plus catch-up or EPI alone. The highest
impact was approximately 5 (Panel F) to 7 (Panel B) deaths averted
per 1000 doses ten years after beginning mass campaigns in settings
where the EIR was naturally at or suppressed to 2 ibpa. In these
settings, RTS,S not only protected those vaccinated, but also
reduced transmission (Figure 3), likely leading to herd immunity and
rapidly increasing impact. As reflected by the ranges in Table 3,
these estimates are most precise for EPI and least precise for mass
campaigns. All of these estimates depend on the assumption of a
persistent effect of vaccination, but can be adjusted to allow for
shorter durations using published calibration data [24].
Discussion
Modeled estimates of the effect of the RTS,S vaccine allow for
comparisons of uncomplicated cases and deaths averted, and the
efficiency of different delivery strategies to avert those cases and
deaths, in a variety of malaria transmission settings.
In most transmission settings studied, an approximately
proportional relationship between the number of deaths averted
and the number of doses administered through EPI, EPI plus
catch-up and EPI plus school-based campaigns, was observed over
the ten year period simulated. That is, among the delivery
strategies that target a portion of the population, the greater the
number of doses administered, the greater the total number of
lives that can be saved.
The EPI strategy immunized the fewest people over ten years,
and consequently averted the fewest deaths, but with a relatively
high efficiency per 1000 doses administered across transmission
settings. This strategy also provided the most consistent impact
across transmission settings studied. EPI has demonstrated its
feasibility and is compatible with current clinical trial and
regulatory plans. The opportunity to make use of the thus far
successful EPI infrastructure is a strong argument to use this
strategy in (all) transmission settings where it is likely to be cost-
effective to deliver RTS,S this way.
Supplementing EPI delivery with a one-time catch-up vaccina-
tion reaching children below 18 months may be particularly
appealing in an environment with decreasing transmission (setting
c). The catch-up delivery round would require additional
investment and planning beyond that seen for EPI, although
most likely less than required for repeated school-based or mass
campaigns.
School-based delivery strategies did not increase efficiency in
any of the transmission settings studied, so its main benefits are in
reaching a greater number of people. A recent pilot of school-
based strategies for delivering human papilloma-virus (HPV)
vaccine could be part of the momentum to strengthen and expand
school-based strategies over time [44].
The findings for mass campaigns were more complex. Mass
campaigns reached many times more people than EPI alone, and
simulations suggested this delivery strategy could be expected to
the population. The vertical axis for each panel is EIR on a log scale measured in infectious bites per person per night. The horizontal axis for each
panel is time in years. The blue line corresponds to the median transmission of the 14 models, while the grey shading corresponds to an envelope
enclosing 95% of all simulations. Panel A: EIR = 11 ibpa; B: EIR = 2 ibpa; C: EIR decreasing from 20 down to 2 ibpa over 10 years; D: EIR increasing after
brief suppression from 2 to 20 ibpa over 10 years; E: EIR increasing from 2 to 20 ibpa after being suppressed for 10 years; F: EIR suppressed from 20
down to 2 ibpa, and subsequently maintained at 2 ibpa.
doi:10.1371/journal.pone.0032587.g003
Table 2. Uncomplicated cases averted with RTS,S by transmission setting and delivery strategy.
Cases/Person-year
(without vaccine) Percentage of cases averted (Range)
Transmission setting EPI
Catch-up
(plus EPI)
School-based
(plus EPI)
Mass
campaign
a) EIR =11 1.63 6.0 (4.8–7.0) 7.1 (5.6–8.4) 12.0 (8.6–13.1) 24.5 (20.2–30.6)
b) EIR =2 1.38 5.2 (4.1–6.0) 6.6 (5.4–7.3) 17.6 (15.0–21.7) 73.0 (70.4–76.5)
c) Decreasing (EIR 20 to 2) 1.35 7.1 (5.5–8.0) 8.6 (6.6–9.7) 14.0 (10.0–16.4) 30.0 (25.4–37.9)
d) Increasing after brief suppression (EIR 2 to 20) 1.96 5.1 (3.7–6.8) 5.2 (3.7–7.0) 11.9 (7.8–20.5) 32.1 (26.4–59.7)
e) Increasing after 10 year suppression (EIR 2 to 20) 2.97 3.4 (2.5–4.5) 4.1 (3.0–5.8) 8.3 (5.2–12.6) 20.7 (16.7–50.2)
f) Suppressed (EIR =2) 1.46 5.1 (3.0–6.1) 6.6 (4.6–7.8) 15.3 (9.9–17.8) 48.5 (20.2–50.1)
g) EIR =20 1.53 6.0 (4.1–7.1) 7.0 (4.4–8.2) 10.0 (5.4–11.6) 15.5 (6.6–20.7)
Legend: The first column presents transmission settings. The second column presents the total estimated cases in the all-ages population of 100,000 people per
person-year in the absence of vaccination. The estimate is the average over a 10 year period. The remaining columns present the percentage of cases averted by each
delivery strategy, as the median and (range) estimated from 14 models.
doi:10.1371/journal.pone.0032587.t002
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avert more cases and deaths in some situations. Highest efficiency
was seen in very low transmission settings (e.g. EIR of 2 ibpa),
whether naturally occurring or achieved by other interventions
(settings b and f). Efficiency decreased as transmission increased,
making mass campaigns much less efficient than EPI at EIRs
above 2 ibpa.
The impact of mass campaigns varied the most between
different transmission settings, and there were wide ranges in the
model predictions. In contrast to EPI, the expected benefits of
mass vaccination were highly sensitive to model assumptions about
transmission heterogeneity and immunity. The amount of field
data on older children in semi-immune populations and adults is
small, and there is a clear need to improve the evidence base for
parameterizing these aspects of the models. Impact estimates from
mass vaccination in low transmission settings were magnified by
herd immunity. Vaccinating a large proportion of the population
could decrease the likelihood that mosquitoes bite a person with
circulating parasites, thereby decreasing the number of infectious
mosquitoes in a region. Herd immunity is unlikely to arise with
EPI strategies given that the vaccinated infants represent a
relatively small portion of the population so would not significantly
impact the number of circulating mosquitoes with parasites.
Part of the uncertainty about impact of mass-vaccination (also
reaching adults) arose because relatively sparse data about disease
incidence in older people were available when the models were
fitted [32,33]. In our models, the main effect of reducing
transmission on disease is to shift morbidity to older ages. It is
not clear how important this shift is in settings where transmission
is currently reducing. If this shift is less important, independently
of the effects of the vaccine, we might have expected to see larger
effects of reducing transmission on morbidity and mortality rates.
In contrast to most field datasets, the presented rates are calculated
over the entire population and simulated events in adults dilute the
effects on children. Thus, caution is advised when interpreting
model results of mass campaigns until further data is available.
Mass vaccination also appears the most distant potential RTS,S
delivery strategy. New clinical trials, in older age groups
potentially with different safety questions and needing different
doses, may be necessary. Regulatory, cost-effectiveness and
feasibility considerations related to mass campaigns of a multi-
dose vaccine given at one-month intervals, may also need to be
addressed. The findings suggest that further work is needed to
more clearly understand the impact and feasibility of mass
campaigns, potentially when partnered with other interventions
to rapidly decrease transmission. The potential for significant
impact in some settings may make it worth beginning to anticipate
such work.
Estimates of efficiency in this paper are expressed using the ratio
of deaths averted per 1000 doses of vaccine. This can be converted
to deaths averted per 1000 vaccinees, a ratio used by the GAVI
Alliance (GAVI) when considering the impact of various vaccines
it supports financially [45]. The ratio of deaths averted by
Figure 4A–F. Uncomplicated cases averted per 1000 doses
administered, by delivery strategy and transmission setting,
over ten years. Legend: Vertical axis for each panel is number of
cumulative uncomplicated cases averted per 1000 doses administered.
Horizontal axis is years. Vaccination is assumed to begin at year one
with the vaccination schedule completed three months later for the first
subjects. Black = EPI; Purple = EPI plus catch-up of children up to 18
months of age; Brown= EPI plus school-based immunization of children
6–11 years of age; Green=Mass campaigns in entire population. Panel
A: EIR = 11 ibpa; B: EIR = 2 ibpa; C: EIR decreasing from 20 down to
2 ibpa over 10 years; D: EIR increasing after brief suppression from 2 to
20 ibpa over 10 years; E: EIR increasing from 2 to 20 ibpa after being
suppressed for 10 years; F: EIR suppressed from 20 down to 2 ibpa, and
subsequently maintained at 2 ibpa.
doi:10.1371/journal.pone.0032587.g004
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pneumococcal conjugate vaccine in African infants is estimated
from trial data to be 7 per 1000 vaccinees (59 deaths averted in
8000 vaccinees) [46]. Immunizing 1000 infants with RTS,S via
EPI, given the coverage assumptions stated earlier, equates to
delivering approximately 2770 doses of vaccine. Given the ratios
under transmission settings above, simulations suggest RTS,S in
EPI would avert 2–4 deaths per 1000 doses, equivalent to 6–11
deaths per 1000 vaccinees. While one should be cautious
comparing data from field studies with those from modeling
studies, these ratios suggest a favorable comparison with the
pneumococcal vaccine, for which implementation planning is
progressing rapidly in Africa and some $3 billion in financing have
been committed [47].
The findings across the different settings suggest that for
understanding the potential impact of pre erythrocytic vaccines, it
is probably sufficient to use fixed transmission settings in modeling
efforts, even for situations where the underlying baseline
transmission is believed to be decreasing or increasing. The
simulations used in this paper used IRS to create trends in
transmission. Effects would have been slower if the transmission
changes were induced by LLIN use, but there is no reason to
assume that the relative impact of the delivery strategies would be
different.
The effect for RTS,S was expected to be at maximum in the
transmission range studied in these simulations (2–20 ibpa). It is
reasonable to expect that EPI, EPI plus catch-up and EPI plus
school-based strategies will have comparable effects to those seen
in this paper at somewhat higher transmission settings than
studied. Although cost-effectiveness estimates for EPI are available
[26], the other impact estimates could be further informed by cost
and cost-effectiveness analyses which were beyond the scope of this
paper.
Conclusion
The development of the RTS,S malaria vaccine is progressing.
If the vaccine is shown to be safe and efficacious in the current
phase III trial, as has been shown in earlier trials, and it is made
available to countries in Africa, there will be a complex decision-
making process to determine how and where it should be used. In
order to help this process, the authors studied the potential impact
and efficiency of RTS,S delivered through various strategies and
under changing levels of malaria transmission patterns, although
findings suggest that it is probably sufficient for future simulations
to consider constant EIR levels. The type of impact sought,
whether on mortality and morbidity, or on transmission as well,
together with assumptions about feasibility of different delivery
strategies, may lead to different conclusions about the role of
RTS,S.
Findings support further investigation of RTS,S to determine its
potential contribution to malaria transmission reduction through
high coverage of an all age population in low transmission settings.
At 2 ibpa, mass campaigns could avert the most deaths and
decrease transmission; however, a lot of uncertainty was associated
with these findings. Also, the feasibility of mass campaigns
delivering a multi-dose immunization requires assessment. Further
consideration of the regulatory implications, clinical studies
required to address questions of the extent of the benefit, and
other product development activities will be important to
anticipate, prior to RTS,S being used in mass campaigns. Such
considerations would benefit from early planning due to their
lengthy nature.
The findings also support going forward with EPI delivery as an
initial strategy for RTS,S. If delivered via established EPI systems,
RTS,S could avert approximately 6–11 deaths per 1000 vaccinees
in all examined settings, an efficiency consistent with or superior to
other new vaccines being implemented across Africa. However, it
would have little effect on transmission when delivered via EPI.
The number of events averted increases somewhat with the EPI
plus catch-up and the EPI plus school-based strategies. The
increase is essentially proportional to the larger population
covered, and because that larger population coverage is modest,
it is not an enormous added benefit. These results, combined with
those of other modeling studies, should provide information to
help policy-makers at international and country-levels to take
evidence-based decisions on optimal strategies to avert malaria
cases and deaths in Africa.
Supporting Information
Text S1 Ensemble Modeling of the Likely Public Health
Impact of a Pre-Erythrocytic Malaria Vaccine.
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Table 3. Deaths averted with RTS,S by transmission setting and delivery strategy.
Deaths/1000 person-
years (without vaccine) Percentage of deaths averted (Range)
Transmission setting EPI
Catch-up (plus
EPI)
School-based (plus
EPI) Mass campaign
a) EIR =11 3.8 13.7 (10.3–16.2) 14.8 (11.9–16.7) 15.9 (10.3–20.9) 18.8 (7.1–25.7)
b) EIR =2 3.7 10.2 (7.2–14.3) 11.9 (9.0–16.7) 22.4 (14.5–26.0) 68.1 (65.5–72.2)
c) Decreasing (EIR 20 to 2) 3.3 15.5 (11.3–17.7) 17.2 (14.1–20.9) 19.0 (12.4–20.7) 25.2 (13.1–32.8)
d) Increasing after brief suppression (EIR
2 to 20)
5.0 10.3 (8.0–11.5) 9.8 (7.3–11.4) 14.9 (9.0–20.1) 28.3 (13.8–58.5)
e) Increasing after 10 year suppression
(EIR 2 to 20)
7.8 6.8 (3.1–8.3) 7.2 (4.9–9.0) 9.4 (3.7–12.1) 14.2 (1.8–42.5)
f) Suppressed (EIR =2) 3.7 10.5 (5.6–12.7) 11.7 (4.4–14.7) 18.7 (10.8–21.1) 45.4 (21.0–47.5)
g) EIR =20 3.8 13.3 (9.6–15.7) 14.0 (9.7–17.8) 13.6 (8.1–18.8) 9.9 (1.6–15.7)
Legend: The first column presents transmission settings. The second column presents the total estimated malaria deaths in the all-ages population of 100,000 people
per person-year in the absence of vaccination. The estimate is the average over a 10 year period. The remaining columns present the percentage of deaths averted by
each delivery strategy, as the median and (range) estimated from 14 models.
doi:10.1371/journal.pone.0032587.t003
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Figure 5A–F. Deaths averted per 1000 population, by transmission setting, over ten years. Legend: The first column corresponds to
vaccine delivered through EPI and the second corresponds to vaccination through mass campaigns to all ages of the population. The vertical axis for
each panel is number of cumulative deaths averted per 1000 population. The horizontal axis for each panel is years. The black lines correspond to the
median effect estimated by each of the 14 models, while the grey shading corresponds to an envelope enclosing 95% of all simulations. Vaccination
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